BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22784013)

  • 1. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
    Kranzler HR; Armeli S; Covault J; Tennen H
    Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
    McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
    Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
    Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
    Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
    Ray LA; Bujarski S; Chin PF; Miotto K
    Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
    Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
    Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
    Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
    Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
    Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
    Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
    Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
    J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
    Witkiewitz K; Roos CR; Mann K; Kranzler HR
    Alcohol Clin Exp Res; 2019 Nov; 43(11):2395-2405. PubMed ID: 31436886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
    Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
    Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
    Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
    Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
    O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
    Bujarski S; MacKillop J; Ray LA
    Exp Clin Psychopharmacol; 2012 Jun; 20(3):181-90. PubMed ID: 22429255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.